Canaccord lowered the firm’s price target on Aptose Biosciences to $8 from $13 and keeps a Buy rating on the shares. The analyst reduced the target due to our lowering of probability of success for luxeptinib in light of the company’s focus on the lead asset, tuspetinib. Canaccord said we continue to base our PT off of expectations for further clinical activity for HM43239 in AML and for luxeptinib in AML and B-cell malignancies at higher doses.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APTO:
- Aptose Biosciences reports Q4 EPS (11c), consensus (11c)
- Aptose Reports Results for the Fourth Quarter and Full Year 2022
- Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
- Aptose Biosciences says immaterial financial exposure to Silicon Valley Bank
- Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
